$HARP is the ticker symbol for Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company. Harpoon is developing a novel class of T cell engagers (TCEs) that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. TCEs are a type of immunotherapy that work by binding to two different targets: a tumor antigen and a T cell receptor. This binding brings the T cell close to the tumor cell, allowing the T cell to kill the tumor cell. Harpoon's TCEs are designed to be highly specific and potent, with the goal of minimizing side effects and maximizing efficacy. Harpoon has a pipeline of TCEs in development for a variety of cancer types, including blood cancers, solid tumors, and pediatric cancers. The company's lead product candidate, HPN424, is a TCE targeting CD47, a protein that is overexpressed on many types of cancer cells. HPN424 is currently in Phase 2 clinical trials for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Harpoon is also developing TCEs targeting other tumor antigens, such as BCMA, CD33, and HER2. The company has a number of partnerships with large pharmaceutical companies, including Bristol-Myers Squibb, AbbVie, and Pfizer, to help develop and commercialize its TCEs. Analysts are generally bullish on Harpoon Therapeutics, with a consensus rating of Moderate Buy. The company has a strong pipeline of TCEs in development, and it is backed by several large pharmaceutical companies. However, Harpoon is still a clinical-stage company, and its TCEs have not yet been approved for commercial use. Investors should carefully consider their own investment goals and risk tolerance before investing in Harpoon Therapeutics. |